Quarterly ResultMay 12, 2026, 07:02 AM
Olema Pharma Anticipates Phase 3 OPERA-01 Data Fall 2026; Q1 Net Loss $53.1M
AI Summary
Olema Pharmaceuticals reported Q1 2026 financial results, including a net loss of $53.1 million, an increase from $30.4 million in Q1 2025, primarily due to higher R&D expenses. The company ended the quarter with $505.3 million in cash, cash equivalents, and marketable securities. Olema also provided significant pipeline updates, anticipating top-line data from its Phase 3 OPERA-01 trial for palazestrant this fall and presenting initial Phase 1 clinical data for OP-3136 at ASCO later this month. Patient enrollment continues for the Phase 3 OPERA-02 trial and other combination studies for palazestrant.
Key Highlights
- Anticipates top-line data from Phase 3 OPERA-01 trial for palazestrant in fall 2026.
- Initial Phase 1 clinical data for OP-3136 to be presented at ASCO later this month.
- Q1 2026 net loss was $53.1 million, compared to $30.4 million in Q1 2025.
- Ended Q1 2026 with $505.3 million in cash, cash equivalents, and marketable securities.
- GAAP R&D expenses increased to $49.2 million in Q1 2026 from $30.6 million in Q1 2025.
- GAAP G&A expenses increased to $8.8 million in Q1 2026 from $4.2 million in Q1 2025.
- Continued patient enrollment in pivotal Phase 3 OPERA-02 trial for palazestrant.